"Thiohydantoins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D013867
|
| MeSH Number(s) |
D03.383.129.308.432.555.868
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiohydantoins".
Below are MeSH descriptors whose meaning is more specific than "Thiohydantoins".
This graph shows the total number of publications written about "Thiohydantoins" by people in this website by year, and whether "Thiohydantoins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thiohydantoins" by people in Profiles.
-
De La Cerda J, Belkoff L, Courtney KD, Diamond E, D'Olimpio J, Dunshee C, Gervasi L, Goodman M, Mittal K, Morris D, Sieber P, Tutrone R, Ryan M, Zhong Y, Ufer M, Shore N. Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial. Target Oncol. 2025 May; 20(3):503-517.
-
Santoni M, Massari F, Rizzo A, Mollica V, Cimadamore A, Montironi R, Battelli N. Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis. Tumori. 2023 Apr; 109(2):157-163.
-
Rizzo A, Oderda M, Mollica V, Merler S, Morelli F, Fragomeno B, Taveri E, Sorgentoni G, Santoni M, Massari F. A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. Anticancer Drugs. 2022 01 01; 33(1):e43-e51.
-
Di Nunno V, Santoni M, Massari F. New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival? Eur Urol Oncol. 2019 07; 2(4):471.